Literature DB >> 8260238

Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates.

Y Remvikos1, M Jouve, P Beuzeboc, P Viehl, H Magdelenat, P Pouillart.   

Abstract

Breast cancer cells from 92 patients were obtained by repeated fine needle sampling and analysed by flow cytometry for cell cycle modifications during neoadjuvant chemotherapy. Modifications of the histograms were observed for 47 of the 71 informative cases (66%), the most frequent concerning S-phase (increase or decrease) and G2M accumulation. These modifications correlated well with the efficacy of cytotoxic chemotherapy (P < 0.0001). A significant relationship between clinical regression and pretreatment proliferative activity was also observed, with 31/35 (89%) responders in the high proliferation group (S-phase fraction > 5% or BrdU labelling index > 3.3%) compared to 20/36 (56%) in the low proliferation group (P < 0.002). For patients undergoing chemotherapy including doxorubicin, a high incidence of G2M accumulation was observed (33%), a modification which was rare (4.5%) for a regimen with no anthracycline, for which S-phase was the most frequently modified cell cycle compartment (64%). The measurement of the pretreatment tumour proliferative activity as well as the early kinetic modifications, as indicators of response, may prove interesting parameters for the future management of neoadjuvant chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8260238     DOI: 10.1016/0959-8049(93)90534-m

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  3 in total

Review 1.  Prognosis and prediction of response in breast cancer: the current role of the main biological markers.

Authors:  A Ravaioli; L Bagli; A Zucchini; F Monti
Journal:  Cell Prolif       Date:  1998 Jun-Aug       Impact factor: 6.831

2.  Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer.

Authors:  J Y Pierga; C Lainé-Bidron; P Beuzeboc; P De Crémoux; P Pouillart; H Magdelénat
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?

Authors:  P Hietanen; C Blomqvist; V M Wasenius; E Niskanen; K Franssila; S Nordling
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.